Cart
sales@molnova.com
GDC-0879
CAS No. 905281-76-7
GDC-0879( GDC0879 | GDC 0879 )
Catalog No. M16507 CAS No. 905281-76-7
A potent and selective B-Raf kinase inhibitor with IC50 of 0.13 nM against purified B-Raf V600E and a cellular pERK IC50 of 63 nM in the MALME-3M cell line.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 41 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 205 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 200MG | 764 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGDC-0879
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective B-Raf kinase inhibitor with IC50 of 0.13 nM against purified B-Raf V600E and a cellular pERK IC50 of 63 nM in the MALME-3M cell line.
-
DescriptionA potent and selective B-Raf kinase inhibitor with IC50 of 0.13 nM against purified B-Raf V600E and a cellular pERK IC50 of 63 nM in the MALME-3M cell line; shows expected activity only against C-Raf against a panel of 140 kinases at 1 uM; shows comparable potency in A375 melanoma and Colo205 colorectal carcinoma cell lines with IC50 of 59 nM and 29 nM for pMEK1 inhibition respectively; shows tumor growth inhibition in A375 xenografts; orally active.Skin Cancer Preclinical.
-
In Vitro——
-
In Vivo——
-
SynonymsGDC0879 | GDC 0879
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorB-Raf
-
Research AreaCancer
-
IndicationSkin Cancer
Chemical Information
-
CAS Number905281-76-7
-
Formula Weight334.3718
-
Molecular FormulaC19H18N4O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESOCCN1N=C(C2=CC=NC=C2)C(C3=CC4=C(/C(CC4)=N/O)C=C3)=C1
-
Chemical Name1H-Inden-1-one, 2,3-dihydro-5-[1-(2-hydroxyethyl)-3-(4-pyridinyl)-1H-pyrazol-4-yl]-, oxime
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Plx-4032
PLX-4032 is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.PLX-4032 and its related analogs are highly potent inhibitors of B-Raf activity, with 3-fold selectivity for the V600E mutation over the wild-type kinase.
-
SU6656
SU 6656 is a selective inhibitor of Src family kinases, with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
-
Locostatin
Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.Locostatin treatment resulted in the activation of the mitogen-activated protein kinase (MAPK) signal pathway (ERK phosphorylation), providing a powerful validation of our targeting protocol.?
